Symbols / FDMT
FDMT Chart
About
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in EmeryVille, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 593.41M |
| Enterprise Value | 292.55M | Income | -209.18M | Sales | 120.00K |
| Book/sh | 7.89 | Cash/sh | 5.34 | Dividend Yield | — |
| Payout | 0.00% | Employees | 227 | IPO | — |
| P/E | — | Forward P/E | -2.99 | PEG | — |
| P/S | 4945.09 | P/B | 1.32 | P/C | — |
| EV/EBITDA | -1.31 | EV/Sales | 2437.92 | Quick Ratio | 8.22 |
| Current Ratio | 8.42 | Debt/Eq | 6.03 | LT Debt/Eq | — |
| EPS (ttm) | -3.75 | EPS next Y | -3.48 | EPS Growth | — |
| Revenue Growth | 29.00% | Earnings | 2026-02-27 | ROA | -27.64% |
| ROE | -45.38% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -655.39% | Profit Margin | 0.00% | Shs Outstand | 51.01M |
| Shs Float | 39.45M | Short Float | 18.88% | Short Ratio | 12.02 |
| Short Interest | — | 52W High | 12.34 | 52W Low | 2.23 |
| Beta | 3.01 | Avg Volume | 897.59K | Volume | 62.76K |
| Target Price | $33.11 | Recom | None | Prev Close | $10.07 |
| Price | $10.39 | Change | 3.14% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$33.11
Mean price target
2. Current target
$10.20
Latest analyst target
3. DCF / Fair value
$-36.54
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.20
Low
$17.00
High
$45.00
Mean
$33.11
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-28 | init | Barclays | — → Overweight | $33 |
| 2025-12-18 | main | Chardan Capital | Buy → Buy | $26 |
| 2025-11-11 | main | RBC Capital | Outperform → Outperform | $32 |
| 2025-11-11 | main | Barclays | Overweight → Overweight | $33 |
| 2025-11-11 | main | Chardan Capital | Buy → Buy | $26 |
| 2025-10-21 | reit | RBC Capital | Outperform → Outperform | $26 |
| 2025-08-12 | main | Roth Capital | Buy → Buy | $38 |
| 2025-08-12 | main | Chardan Capital | Buy → Buy | $25 |
| 2025-08-01 | main | Chardan Capital | Buy → Buy | $25 |
| 2025-07-03 | main | Chardan Capital | Buy → Buy | $25 |
| 2025-05-09 | main | Chardan Capital | Buy → Buy | $25 |
| 2025-05-09 | main | Goldman Sachs | Buy → Buy | $44 |
| 2025-05-09 | main | Barclays | Overweight → Overweight | $38 |
| 2025-03-10 | main | B of A Securities | Buy → Buy | $40 |
| 2025-03-04 | main | Chardan Capital | Buy → Buy | $28 |
| 2025-03-03 | main | RBC Capital | Outperform → Outperform | $35 |
| 2025-03-03 | reit | HC Wainwright & Co. | Buy → Buy | $36 |
| 2025-02-11 | main | Chardan Capital | Buy → Buy | $30 |
| 2025-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $36 |
| 2025-01-13 | main | Morgan Stanley | Underweight → Underweight | $6 |
- Biotech 4DMT heads to three March healthcare investor conferences - Stock Titan hu, 19 Feb 2026 13
- Price-Driven Insight from (FDMT) for Rule-Based Strategy - Stock Traders Daily Fri, 20 Feb 2026 23
- $FDMT stock is down 15% today. Here's what we see in our data. - Quiver Quantitative Wed, 17 Dec 2025 08
- Is 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Invest In Growth? - Yahoo Finance Fri, 03 Oct 2025 07
- FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease - Stocktwits hu, 06 Nov 2025 11
- Barclays Maintains 4D Molecular Therapeutics (FDMT) Overweight Recommendation - Nasdaq ue, 11 Nov 2025 08
- Bizily, 4D Molecular Therapeutics CLO, sells $16,627 in FDMT stock - Investing.com Mon, 20 Oct 2025 07
- Institutional investors own a significant stake of 49% in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - simplywall.st Wed, 12 Nov 2025 08
- Biotech 4DMT hands 23,600 stock units to four new hires under award plan - Stock Titan Sat, 17 Jan 2026 08
- New Analyst Forecast: $FDMT Given $33 Price Target - Quiver Quantitative Wed, 28 Jan 2026 08
- 4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates - Nasdaq Mon, 11 Aug 2025 07
- Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) - Yahoo Finance Mon, 02 Feb 2026 08
- Understanding the Setup: (FDMT) and Scalable Risk - Stock Traders Daily ue, 16 Dec 2025 08
- Wet AMD trial fills fast as 4D-150 targets fewer eye injections - Stock Titan Mon, 09 Feb 2026 08
- $FDMT stock is up 10% today. Here's what we see in our data. - Quiver Quantitative Wed, 14 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 389 | 3377.0 | — | Sale at price 8.68 per share. | GUPTA ASHOO | Officer | — | 2025-12-19 00:00:00 | D |
| 1 | 1086 | nan | — | — | GUPTA ASHOO | Officer | — | 2025-12-19 00:00:00 | D |
| 2 | 1635 | 17822.0 | — | Sale at price 10.90 per share. | BIZILY SCOTT | Officer | — | 2025-12-16 00:00:00 | D |
| 3 | 1635 | 6769.0 | — | Conversion of Exercise of derivative security at price 4.14 per share. | BIZILY SCOTT | Officer | — | 2025-12-16 00:00:00 | D |
| 4 | 9333 | 10640.0 | — | Conversion of Exercise of derivative security at price 1.14 per share. | THEUER CHARLES P. | Director | — | 2025-12-12 00:00:00 | D |
| 5 | 1635 | 17315.0 | — | Sale at price 10.59 per share. | BIZILY SCOTT | Officer | — | 2025-11-17 00:00:00 | D |
| 6 | 1635 | 6769.0 | — | Conversion of Exercise of derivative security at price 4.14 per share. | BIZILY SCOTT | Officer | — | 2025-11-17 00:00:00 | D |
| 7 | 2678 | 32136.0 | — | Sale at price 12.00 per share. | BIZILY SCOTT | Officer | — | 2025-10-24 00:00:00 | D |
| 8 | 1084 | 7035.0 | — | Conversion of Exercise of derivative security at price 6.49 per share. | BIZILY SCOTT | Officer | — | 2025-10-24 00:00:00 | D |
| 9 | 1635 | 16628.0 | — | Sale at price 10.17 per share. | BIZILY SCOTT | Officer | — | 2025-10-16 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -181.14M | -107.12M | -106.15M | -68.31M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -160.87M | -100.84M | -107.49M | -71.32M |
| ReconciledDepreciation | 6.71M | 5.75M | 3.88M | 3.02M |
| EBITDA | -181.14M | -107.12M | -106.15M | -68.31M |
| EBIT | -187.84M | -112.87M | -110.03M | -71.33M |
| NetInterestIncome | 27.05M | 12.21M | 2.57M | 137.00K |
| InterestIncome | 27.05M | 12.21M | 2.57M | 137.00K |
| NormalizedIncome | -160.87M | -100.84M | -107.49M | -71.32M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -160.87M | -100.84M | -107.49M | -71.32M |
| TotalExpenses | 187.88M | 133.59M | 113.16M | 89.37M |
| TotalOperatingIncomeAsReported | -187.84M | -112.87M | -110.03M | -71.33M |
| DilutedAverageShares | 53.94M | 39.13M | 32.35M | 27.73M |
| BasicAverageShares | 53.94M | 39.13M | 32.35M | 27.73M |
| DilutedEPS | -2.98 | -2.58 | -3.32 | -2.57 |
| BasicEPS | -2.98 | -2.58 | -3.32 | -2.57 |
| DilutedNIAvailtoComStockholders | -160.87M | -100.84M | -107.49M | -71.32M |
| NetIncomeCommonStockholders | -160.87M | -100.84M | -107.49M | -71.32M |
| NetIncome | -160.87M | -100.84M | -107.49M | -71.32M |
| NetIncomeIncludingNoncontrollingInterests | -160.87M | -100.84M | -107.49M | -71.32M |
| NetIncomeContinuousOperations | -160.87M | -100.84M | -107.49M | -71.32M |
| PretaxIncome | -160.87M | -100.84M | -107.49M | -71.32M |
| OtherIncomeExpense | -77.00K | -181.00K | -35.00K | -121.00K |
| OtherNonOperatingIncomeExpenses | -77.00K | -181.00K | -35.00K | -121.00K |
| NetNonOperatingInterestIncomeExpense | 27.05M | 12.21M | 2.57M | 137.00K |
| InterestIncomeNonOperating | 27.05M | 12.21M | 2.57M | 137.00K |
| OperatingIncome | -187.84M | -112.87M | -110.03M | -71.33M |
| OperatingExpense | 187.88M | 133.59M | 113.16M | 89.37M |
| ResearchAndDevelopment | 141.30M | 97.10M | 80.25M | 61.36M |
| SellingGeneralAndAdministration | 46.58M | 36.49M | 32.91M | 28.01M |
| GeneralAndAdministrativeExpense | 46.58M | 36.49M | 32.91M | 28.01M |
| OtherGandA | 46.58M | 36.49M | 32.91M | 28.01M |
| TotalRevenue | 37.00K | 20.72M | 3.13M | 18.04M |
| OperatingRevenue | 37.00K | 20.72M | 3.13M | 18.04M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 45.79M | 43.08M | 32.63M | 32.22M |
| ShareIssued | 45.79M | 43.08M | 32.63M | 32.22M |
| TotalDebt | 24.61M | 14.67M | 16.12M | 16.45M |
| TangibleBookValue | 510.61M | 307.83M | 231.34M | 319.11M |
| InvestedCapital | 510.61M | 307.83M | 231.34M | 319.11M |
| WorkingCapital | 405.78M | 277.64M | 204.78M | 239.94M |
| NetTangibleAssets | 510.61M | 307.83M | 231.34M | 319.11M |
| CapitalLeaseObligations | 24.61M | 14.67M | 16.12M | 16.45M |
| CommonStockEquity | 510.61M | 307.83M | 231.34M | 319.11M |
| TotalCapitalization | 510.61M | 307.83M | 231.34M | 319.11M |
| TotalEquityGrossMinorityInterest | 510.61M | 307.83M | 231.34M | 319.11M |
| StockholdersEquity | 510.61M | 307.83M | 231.34M | 319.11M |
| GainsLossesNotAffectingRetainedEarnings | 229.00K | 16.00K | -1.20M | -423.00K |
| OtherEquityAdjustments | 229.00K | 16.00K | -1.20M | -423.00K |
| RetainedEarnings | -576.20M | -415.33M | -314.49M | -207.00M |
| AdditionalPaidInCapital | 1.09B | 723.14M | 547.02M | 526.52M |
| CapitalStock | 5.00K | 4.00K | 3.00K | 3.00K |
| CommonStock | 5.00K | 4.00K | 3.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 49.78M | 32.06M | 30.51M | 34.38M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 20.63M | 13.11M | 14.78M | 18.04M |
| OtherNonCurrentLiabilities | 193.00K | 248.00K | 21.00K | 120.00K |
| DerivativeProductLiabilities | 410.00K | 369.00K | 212.00K | 214.00K |
| TradeandOtherPayablesNonCurrent | 120.00K | |||
| NonCurrentDeferredLiabilities | 1.06M | 972.00K | 1.08M | 2.49M |
| NonCurrentDeferredRevenue | 1.06M | 972.00K | 1.08M | 2.49M |
| LongTermDebtAndCapitalLeaseObligation | 18.97M | 11.52M | 13.47M | 15.22M |
| LongTermCapitalLeaseObligation | 18.97M | 11.52M | 13.47M | 15.22M |
| CurrentLiabilities | 29.15M | 18.95M | 15.73M | 16.34M |
| CurrentDeferredLiabilities | 257.00K | 273.00K | 884.00K | 2.60M |
| CurrentDeferredRevenue | 257.00K | 273.00K | 884.00K | 2.60M |
| CurrentDebtAndCapitalLeaseObligation | 5.64M | 3.15M | 2.65M | 1.23M |
| CurrentCapitalLeaseObligation | 5.64M | 3.15M | 2.65M | 1.23M |
| PayablesAndAccruedExpenses | 23.25M | 15.53M | 12.19M | 12.51M |
| CurrentAccruedExpenses | 18.87M | 12.01M | 8.87M | 7.74M |
| Payables | 4.39M | 3.52M | 3.32M | 4.76M |
| AccountsPayable | 4.39M | 3.52M | 3.32M | 4.76M |
| TotalAssets | 560.38M | 339.89M | 261.85M | 353.49M |
| TotalNonCurrentAssets | 125.45M | 43.30M | 41.34M | 97.21M |
| OtherNonCurrentAssets | 4.26M | 684.00K | 1.08M | 602.00K |
| InvestmentsAndAdvances | 80.58M | 10.95M | 4.91M | 67.65M |
| InvestmentinFinancialAssets | 80.58M | 10.95M | 4.91M | 67.65M |
| AvailableForSaleSecurities | 80.58M | 10.95M | 4.91M | 67.65M |
| NetPPE | 40.61M | 31.66M | 35.35M | 28.95M |
| AccumulatedDepreciation | -16.59M | -11.93M | -7.73M | -5.33M |
| GrossPPE | 57.19M | 43.60M | 43.08M | 34.28M |
| Leases | 17.76M | 16.90M | 16.90M | 2.53M |
| ConstructionInProgress | 1.18M | 550.00K | 476.00K | 10.07M |
| OtherProperties | 11.54M | 13.09M | 14.56M | |
| MachineryFurnitureEquipment | 17.17M | 14.61M | 12.61M | 7.12M |
| BuildingsAndImprovements | 21.07M | 11.54M | 13.09M | 14.56M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 434.93M | 296.59M | 220.51M | 256.28M |
| OtherCurrentAssets | 10.05M | 8.36M | 6.96M | 8.46M |
| PrepaidAssets | 8.46M | |||
| Receivables | 0.00 | 47.00K | ||
| AccountsReceivable | 0.00 | 47.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 424.88M | 288.23M | 213.55M | 247.78M |
| OtherShortTermInvestments | 275.54M | 39.12M | 161.20M | 94.78M |
| CashAndCashEquivalents | 149.34M | 249.11M | 52.35M | 153.00M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -138.37M | -78.56M | -98.22M | -78.24M |
| IssuanceOfCapitalStock | 331.41M | 148.34M | 0.00 | 114.30M |
| CapitalExpenditure | -3.79M | -2.77M | -11.54M | -9.11M |
| EndCashPosition | 149.34M | 249.11M | 52.35M | 153.00M |
| BeginningCashPosition | 249.11M | 52.35M | 153.00M | 276.73M |
| ChangesInCash | -99.77M | 196.76M | -100.65M | -123.72M |
| FinancingCashFlow | 337.25M | 156.83M | 3.08M | 118.09M |
| CashFlowFromContinuingFinancingActivities | 337.25M | 156.83M | 3.08M | 118.09M |
| NetOtherFinancingCharges | -468.00K | |||
| ProceedsFromStockOptionExercised | 5.84M | 8.49M | 3.55M | 3.79M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 331.41M | 148.34M | 0.00 | 114.30M |
| CommonStockIssuance | 331.41M | 148.34M | 0.00 | 114.30M |
| InvestingCashFlow | -302.44M | 115.72M | -17.05M | -172.68M |
| CashFlowFromContinuingInvestingActivities | -302.44M | 115.72M | -17.05M | -172.68M |
| NetInvestmentPurchaseAndSale | -298.65M | 118.49M | -5.51M | -163.57M |
| SaleOfInvestment | 169.00M | 173.29M | 147.80M | 5.00M |
| PurchaseOfInvestment | -467.65M | -54.80M | -153.31M | -168.57M |
| NetPPEPurchaseAndSale | -3.79M | -2.77M | -11.54M | -9.11M |
| PurchaseOfPPE | -3.79M | -2.77M | -11.54M | -9.11M |
| OperatingCashFlow | -134.59M | -75.79M | -86.69M | -69.13M |
| CashFlowFromContinuingOperatingActivities | -134.59M | -75.79M | -86.69M | -69.13M |
| ChangeInWorkingCapital | 537.00K | 630.00K | -1.34M | -15.53M |
| ChangeInOtherWorkingCapital | 69.00K | -715.00K | -3.13M | -14.72M |
| ChangeInOtherCurrentLiabilities | -1.65M | -1.45M | -324.00K | -1.00M |
| ChangeInOtherCurrentAssets | -3.58M | -70.00K | -11.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 7.39M | 4.27M | 847.00K | 2.97M |
| ChangeInAccruedExpense | 6.52M | 3.37M | 2.48M | 689.00K |
| ChangeInPayable | 871.00K | 896.00K | -1.64M | 2.29M |
| ChangeInAccountPayable | 871.00K | 896.00K | -1.64M | 2.29M |
| ChangeInPrepaidAssets | -1.70M | -1.40M | 1.24M | -4.22M |
| ChangeInReceivables | 0.00 | 47.00K | 1.44M | |
| ChangesInAccountReceivables | 0.00 | 47.00K | 1.44M | |
| StockBasedCompensation | 26.12M | 19.66M | 17.12M | 13.80M |
| AmortizationOfSecurities | -7.18M | -1.24M | 1.06M | 719.00K |
| DepreciationAmortizationDepletion | 6.71M | 5.75M | 3.88M | 3.02M |
| DepreciationAndAmortization | 6.71M | 5.75M | 3.88M | 3.02M |
| Depreciation | 6.71M | 5.75M | 3.88M | 3.02M |
| OperatingGainsLosses | 107.00K | 245.00K | 85.00K | 179.00K |
| GainLossOnInvestmentSecurities | 107.00K | 245.00K | 85.00K | 179.00K |
| NetIncomeFromContinuingOperations | -160.87M | -100.84M | -107.49M | -71.32M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for FDMT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|